渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 12-20 15:59:59 EST

146.47

-0.92

-0.62%

盘后145.70

-0.77-0.53%

19:57 EST

最高147.85	最低145.07	成交量577.61万
今开145.64	昨收147.39	日振幅1.89%
总市值213.44亿	流通市值212.72亿	总股本1.46亿
成交额8.46亿	换手率3.98%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":146.47,"timestamp":1734728399999,"preClose":147.39,"halted":0,"volume":5776142,"hourTrading":{"tag":"盘后","latestPrice":145.6979,"preClose":146.47,"latestTime":"19:57 EST","volume":367436,"amount":53818680.92408,"timestamp":1734742648335},"delay":0,"floatShares":145229460,"shares":145719340,"eps":11.061496,"marketStatus":"休市中","marketStatusCode":7,"change":-0.92,"latestTime":"12-20 15:59:59 EST","open":145.64,"high":147.85,"low":145.0709,"amount":845806826.8162,"amplitude":0.018855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.061496,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":685080000000,"adjPreClose":147.39,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":145.42,"preClose":147.39,"latestTime":"09:29 EST","volume":8667,"amount":1262765.08602,"timestamp":1734704999999},"postHourTrading":{"tag":"盘后","latestPrice":145.6979,"preClose":146.47,"latestTime":"19:57 EST","volume":367436,"amount":53818680.92408,"timestamp":1734742648335},"volumeRatio":3.59486211590893,"impliedVol":0.3707,"impliedVolPercentile":0.8452},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2492994945","title":"礼来公司的阿尔茨海默氏症疗法在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2492994945","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492994945?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:47","pubTimestamp":1734486463,"startTime":"0","endTime":"0","summary":"    路透12月18日 - 礼来公司周二晚些时候表示，中国医疗监管机构已批准礼来  治疗早期阿尔茨海默氏症的药物，这是继今年1月卫材  和百健  的Leqembi获得 。礼来公司在一份声明中说，中国是继美国、日本和英国之后，该疗法获得批准的第四个主要市场。与Leqembi一样，礼来的Kisunla旨在清除大脑中一种名为β-淀粉样蛋白的阿尔茨海默氏症相关蛋白。该疗法目前正在接受欧盟药品监管机构的审查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ99366536.SGD","SGXZ57979304.SGD","LU0122379950.USD","LU2089984988.USD","LU2237443382.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU0820561909.HKD","LU1623119135.USD","IE0009355771.USD","SG9999014914.USD","LU0109394709.USD","LU0820561818.USD","LU0943347566.SGD","SGXZ51526630.SGD","SG9999014906.USD","IE00BJLML261.HKD","IE00B894F039.SGD","LLY","LU1868836914.USD","IE0002141913.USD","SG9999013999.USD","LU1988902786.USD","LU0471298777.SGD","LU0456855351.SGD","BK4516","LU0471298694.HKD","IE00B1BXHZ80.USD","LU1023059063.AUD","SG9999015952.SGD","LU0289739699.SGD","LU0882574055.USD","LU1868837300.USD","LU2237443549.SGD","LU2237443978.SGD","LU2265009873.SGD","SG9999017495.SGD","SGXZ31699556.SGD","BK4588","BIIB","LU0417517546.SGD","LU2264538146.SGD","BK4532","LU2361044865.SGD","LU1814569148.SGD","LU0689472784.USD","LU1974910355.USD","LU1280957306.USD","LU0006306889.USD"],"gpt_icon":1},{"id":"2492609381","title":"2024年最适合“避税”的亏损了结票","url":"https://stock-news.laohu8.com/highlight/detail?id=2492609381","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492609381?lang=zh_cn&edition=full","pubTime":"2024-12-17 10:17","pubTimestamp":1734401820,"startTime":"0","endTime":"0","summary":"税收损失抛售是指投资者为了减少应纳税收入，有意出售价格下跌、处于亏损状态的证券。通过这种方式，投资者可以用投资损失来抵消资本利得。随着税收损失抛售接近尾声，表现最差的股票会出现反弹交易。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-17/doc-inczttzv1781866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4579","NFE","SWKS","BK4154","BK4100","MBLY","RIVN","LU0234570918.USD","LU2098885051.SGD","BK4532","BK4099","BK4566","LU0266013472.USD","LU0690374615.EUR","BK4535","ETSY","NKE","LU0321505439.SGD","LU0211331839.USD","BK4551","BK4548","BIIB","AGL","BK4138","HUM","IE00B19Z9P08.USD","INTC","U","BK4588","BK4128","LU0070302665.USD","LU0238689110.USD","IE00BN0W2T93.GBP","SIRI","LCID","WBA","LU0417517546.SGD","STNE","BK4585","HAL","BK4139","BK4504","BK4581","LU1093756168.USD","LU0823414478.USD","BK4534","EL","SEDG","LU1303367103.USD"],"gpt_icon":1},{"id":"2491933296","title":"美国机构表示，私人医疗保险计划必须涵盖百健公司的 ALS 药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2491933296","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491933296?lang=zh_cn&edition=full","pubTime":"2024-12-13 01:35","pubTimestamp":1734024928,"startTime":"0","endTime":"0","summary":"Qalsody去年获得了美国食品和药物管理局的加速批准 ，但CMS表示，它发现许多覆盖65岁及以上成年人或残疾人的医疗保险优势计划拒绝承保该药物，称其为 \"试验性和研究性 \"药物。美国食品和药物管理局的加速审批途径允许提前批准治疗严重疾病的药物。该机构在 12 月 9 日的一份备忘录中说，CMS 并没有对通过 FDA 加速审批和传统审批上市的药物进行区分，并指示保险公司 立即停止拒绝承保该药物的政策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","CMS","LU0889565916.HKD","BIIB","BK4208","LU1894683348.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU2637428348.USD","LU2346227817.USD","LU1894683264.USD","BK4585","BK4139","BK4588","BK4532","LU0234570918.USD","BK4533"],"gpt_icon":1},{"id":"2489263134","title":"【券商聚焦】花旗：艾伯维(ABBV)与施贵宝(BMY)增长潜力显著 行业聚焦商业化与新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2489263134","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489263134?lang=zh_cn&edition=full","pubTime":"2024-12-06 10:53","pubTimestamp":1733453617,"startTime":"0","endTime":"0","summary":"会议重点讨论了艾伯维和施贵宝等公司的最新商业执行情况、临床催化剂以及近期推出的产品和标签扩展机会。关于艾伯维，花旗认为公司的重点将继续是Skyrizi和Rinvoq的商业化执行，以及其美容业务的反弹潜力和emraclidine的下一步计划。Skyrizi在溃疡性结肠炎中的增长与克罗恩病的增长相一致，显示出高效力和市场对生物制剂的高接受度。花旗对该公司维持“买入”评级，目标价215美元。对于百时美施贵宝，花旗认为公司的新药上市和管线是缓解收入低谷的关键。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NjJlY2NjZTdjZjEwMTc4NjkxNjc4NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjJlY2NjZTdjZjEwMTc4NjkxNjc4NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282857","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJLML261.HKD","LU2462157665.USD","LU0985481810.HKD","LU0198837287.USD","LU2417539215.USD","LU1267930490.SGD","LLY","LU0170899867.USD","SG9999013999.USD","LU0128525689.USD","LU0321505868.SGD","LU0417517546.SGD","LU2602419157.SGD","LU0738911758.USD","SG9999015978.USD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU2324357040.USD","BK4599","BMY","LU0943347566.SGD","LU1366192091.USD","LU0949170772.SGD","LU1670710588.SGD","LU0029864427.USD","BIIB","LU0203202063.USD","LU0211327993.USD","LU0661504455.SGD","LU2265009873.SGD","BK4566","IE00B3PB1722.GBP","LU1571399168.USD","IE00BJT1NW94.SGD","LU1989771016.USD","BK4581","IE00B2B36J28.USD","LU0310800965.SGD","LU1003077747.HKD","LU0354030511.USD","ABBV","LU2491050154.USD","LU0385154629.USD","LU2264538146.SGD","LU2361045086.USD","IE00BDGV0183.EUR","LU0256863902.USD","LU1791807156.HKD","IE00B4R5TH58.HKD","LU1934455194.USD"],"gpt_icon":1},{"id":"2488159651","title":"特朗普研发政策引爆现金流！这些公司迎来“财务春天”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2488159651","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488159651?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:44","pubTimestamp":1733309086,"startTime":"0","endTime":"0","summary":"特朗普的研发新政可能为美国企业带来一场“现金流革命”！通过允许公司即时记录研发支出，企业不仅能减少税负，还能大幅提升资金流动。","market":"hk","thumbnail":"https://static.tigerbbs.com/ce3169183f95efe0c5e26aef37b958ea","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ce3169183f95efe0c5e26aef37b958ea"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=155116&type=news&data_type=0","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["GILD","BK4524","LU1814569148.SGD","LU2756315664.SGD","IE00B19Z9505.USD","BK4227","BK4566","LU2403377893.USD","LU0265550946.USD","LU1074936037.SGD","LU1366192091.USD","LU1242518857.USD","LU2054465674.USD","MRK","SG9999013999.USD","LU1066051225.USD","SGXZ99366536.SGD","BK4550","ZM","IE0004445015.USD","LU1839511570.USD","LU0795875169.SGD","SG9999015945.SGD","LU2112291526.USD","LU1670711123.USD","LU2213496289.HKD","LU1430594728.SGD","LU2360106780.USD","LU2133065610.SGD","LU0058720904.USD","LU2065171402.SGD","LU0882574139.USD","META","LU1057294990.SGD","LYFT","LU0912757837.SGD","LU1116320901.HKD","IE000M9KFDE8.USD","IE00B19Z8W00.USD","LU0106261372.USD","IE00BK4W5M84.HKD","BIIB","IE00BMPRXQ63.HKD","LU0097036916.USD","IE00BKDWB100.SGD","SG9999014567.USD","PYPL","EA","LU0079474960.USD","BK4085"],"gpt_icon":1},{"id":"2488946447","title":"百健公司预计阿尔茨海默氏症药物 Leqembi 近期将实现稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2488946447","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488946447?lang=zh_cn&edition=full","pubTime":"2024-12-03 22:53","pubTimestamp":1733237597,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社12月3日 - Biogen 公司的一位高管周二在一次医疗保健会议上表示，该公司预计其备受关注的阿尔茨海默病药物 Leqembi 短期内将在美国呈现 \"线性增长趋势\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百健公司预计阿尔茨海默氏症药物 Leqembi 近期将实现稳步增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU0109394709.USD","BIIB","LU0889565916.HKD","BK4533","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0320765992.SGD","IE00B19Z9P08.USD","BK4532","LU0234570918.USD","BK4585"],"gpt_icon":0},{"id":"2488965821","title":"2025年最具上涨空间的低价股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488965821","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488965821?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:13","pubTimestamp":1733206410,"startTime":"0","endTime":"0","summary":"摩根大通在11月25日的客户报告中表示：“展望2025年，生物科技的基本面预计将大体维持不变，随着企业在临床和监管上取得突破并在商业领域执行力强劲，这进一步凸显了创新的价值。”其中，AES的预期上涨空间最大（56%），动态市盈率最低，仅为6.6。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/03141345946693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0130518102.USD","SDS","SPXU","LU1720051017.SGD","UPRO","LU2468319806.SGD","DVN","LU1316542783.SGD","LU0648000940.SGD","BIIB","LU2357305700.SGD","CNC","IE00B19Z3B42.SGD",".SPX","BK4550","IE00B19Z9Z06.USD","LU0823434583.USD","LU0823434740.USD","LU2211814178.USD","IE0034235188.USD","SPY","AES","IVV","IE00B3CCJ633.GBP","BK4596","LU1201861249.SGD","LU0477156797.USD","LU0114720955.EUR","LU1366333091.USD","LU0320765992.SGD","LU0889565916.HKD","REGN","LU0061475181.USD","OEX","LU0823416689.USD","SSO","LU2272731782.SGD","OEF","FSLR","GB00BDT5M118.USD","SH","LU0056508442.USD","LU0157215616.USD","ESmain","MU","LU0792757196.USD","SLB","LU2357125470.USD","BK4554","LU2272731865.HKD"],"gpt_icon":1},{"id":"1114626362","title":"分析师“盯上”这些便宜股，预测2025年有很大的上涨潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1114626362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114626362?lang=zh_cn&edition=full","pubTime":"2024-12-02 10:34","pubTimestamp":1733106875,"startTime":"0","endTime":"0","summary":"30只成分股的道琼斯指数在最新一周上涨了1.4%，标准普尔500指数和纳斯达克综合指数也分别上涨了1.1%。尽管今年市场上涨，但根据多个指标，仍有许多公司未得到充分的认可。但接受伦敦证券交易所调查的分析师给出的一致目标价意味着该股还有超过56%的上涨空间。AES 的预期上涨空间是同类公司中最高的（56%），预期市盈率最低，为 6.6。部分分析师还看好医疗公司Centene、芯片制造商美光科技以及太阳能电池板制造商First Solar等在2025年的表现。","market":"us","thumbnail":"https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","AES"],"gpt_icon":1},{"id":"2486059932","title":"Biohaven 的脊髓性肌肉萎缩症药物未能达到研究目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2486059932","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486059932?lang=zh_cn&edition=full","pubTime":"2024-11-26 03:06","pubTimestamp":1732561590,"startTime":"0","endTime":"0","summary":"更新 3-Biohaven 的脊髓性肌肉萎缩症药物未能达到研究目标第 1 段增加了岩石学者股份，第 9 段增加了分析师评论Mariam Sunny. Biohaven的治疗药物taldefgrobep alfa正在脊髓性肌萎缩症患者中进行试验，这是全球婴儿死亡的主要遗传原因。Biohaven对269名年龄在4至21岁之间、患有任何SMA类型的参与者进行了测试，无论其行走能力如何。Biohaven公司计划在2024年第四季度开始一项中期研究，测试该药物治疗肥胖症的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3T3MW0TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BIIB","BK4585","LU1093756325.SGD","LU0234570918.USD","LU1093756168.USD","BK4532","IE00B894F039.SGD","IE00B19Z9Z06.USD","BHVN","LU0109394709.USD","SRRK","BK4139","LU0889565916.HKD","BK4588","PTCT","IE00B19Z9P08.USD","BK4533"],"gpt_icon":0},{"id":"2484607758","title":"美股走势-Henry Schein Inc、Palantir Technologies、Uber Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2484607758","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484607758?lang=zh_cn&edition=full","pubTime":"2024-11-19 03:12","pubTimestamp":1731957174,"startTime":"0","endTime":"0","summary":".N美国东部时间13:31，道琼斯工业平均指数.DJI下跌0.12%，报43,394.67点。标普500指数.SPX上涨0.42%，报5894.99点；纳斯达克综合指数.IXIC上涨0.62%，报18798.28点。标准普尔 500 指数.PG.INX百分比涨幅前三名是： ** 超级微型计算机公司SMCI.O，上涨 20.2. ** Henry Schein Inc HSIC.O，上涨 6.9 标普500指数.PL.INX跌幅前三名： ** Amentum Holdings Inc AMTM.N，下跌 9.0. 纽约证券交易所.PG.N百分比涨幅前三名： ** Finance of America Companies Inc FOA.N，上涨 21.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HPE","MBI","MRNA","NVDU","NEM","BIIB","MSTR","LUV","NKE","NVD3.UK","HSIC","VSCO","PPTA","SNVD.UK","AEO","JBLU","GAP","CMAX","LBRT","HOOD","DE","TSLA","GL","AILE","TWST","NVDA","CVS","BBWI","VLY","NVD2.UK","NVDS.UK","MARA","NVD","TPR","BTBT","3NVD.UK","NTLA","GRNT","WBD","NVDL","DAL","ASB","DCOM","UAL","2NVD.UK","NVDY","HIMS","NVDX","LLY"],"gpt_icon":1},{"id":"2484670973","title":"BUZZ--美国股票走势-特斯拉公司、帕兰提尔科技公司和超微计算机公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2484670973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484670973?lang=zh_cn&edition=full","pubTime":"2024-11-19 00:14","pubTimestamp":1731946466,"startTime":"0","endTime":"0","summary":"美国东部时间10:31，道琼斯工业平均指数  下跌0.18%，报43366.20点；标普500指数  上涨0.33%，报5889.99点；纳斯达克综合指数  上涨0.76%，报18821.61点。标准普尔 500 指数  百分比涨幅前三名是：** 超级微型计算机公司  ，上涨 8.5 ** 特斯拉  ，上涨8.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDY","DE","MBI","TSLA","UBER","HPE","CVS","BBWI","TSLL","GAP","AEO","DOG","AILE","DXD","AKA","NTLA","ASB","LBRT","SNVD.UK","NVDS","VLY","GL","NVDA","DCOM",".IXIC","PLTR","NQmain","MNQmain",".SPX","SQQQ","DJX","BIIB","NEM","TWST","VSCO","AMTM","WBD","TPR","PPTA","CMAX","SDOW",".DJI"],"gpt_icon":1},{"id":"2484676433","title":"BUZZ--美国股票走势-银矿商、Intellia、Robinhood","url":"https://stock-news.laohu8.com/highlight/detail?id=2484676433","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484676433?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:45","pubTimestamp":1731941147,"startTime":"0","endTime":"0","summary":".N ** 惠普公司HPE.N： BUZZ - 在券商将其评级提升至 \"强烈买入 \"后上涨 nL4N3MP0MD。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP129:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDU","MRNA","IE00B3M56506.USD","NEM","SNVD.UK","BK4587","VLY","HIMS","LU1280957306.USD","LU1366192091.USD","LU2491050154.USD","NVDS.UK","NVDS","LBRT","IE0004445239.USD","WBD","NVDD","NVDY","TSLA","NVDX","HPE","NVDA","LU1839511570.USD","CMAX","NTLA","NVDL","3NVD.UK","HL","CVS","PPTA","TPR","HOOD","HK0000306701.USD","ASB","NVD","LU0278409577.USD","BK4023","BIIB","TWST","NVD2.UK","DCOM","BK4532","LU2290526834.HKD","GL","BK4529","2NVD.UK","CDE","NVD3.UK","BTBT"],"gpt_icon":1},{"id":"2484137678","title":"BUZZ-Needham下调百健评级至 \"持有\"，原因是阿尔茨海默氏症药物采用缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2484137678","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484137678?lang=zh_cn&edition=full","pubTime":"2024-11-18 21:58","pubTimestamp":1731938310,"startTime":"0","endTime":"0","summary":"BUZZ-Needham下调百健评级至 \"持有\"，原因是阿尔茨海默氏症药物采用缓慢11月18日 -  ** 百健BIIB.O股价在收盘前下跌~1%至158.41美元  ** 券商Needham将百健BIIB.O的评级从 \"买入 \"下调至 \"持有\"，理由是明年该股没有 \"有意义的上涨来源\"，而且其阿尔茨海默氏症药物Leqembi的销售增长缓慢。** Needham称，与医生和医疗保健专家的调查显示，Leqembi的销售增长将 \"保持缓慢\"，并将2024年的预期下调了16%，降至约2.05亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LLY"],"gpt_icon":1},{"id":"2483630089","title":"美国研究综述-应用材料公司、迪士尼、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630089","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630089?lang=zh_cn&edition=full","pubTime":"2024-11-16 01:28","pubTimestamp":1731691712,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、迪士尼、沃尔玛路透11月15日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括应用材料公司、迪士尼和沃尔玛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4T3MM1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADSK","BTM","BV","AGYS","ASND","LNG","CABA","BIIB","BMY","IE00BBT3K403.USD","AKYA","LU0354030511.USD","ASTS","LU1861217088.USD","BL","AFG","AESI","AHCO","LU1074936037.SGD","AHR","AROC","AAP","ASB","LU0868494708.USD","APH","AMAT","ALGT","BRX","BAC","BKR","BRZE","IE00BKVL7J92.USD","LU1032466523.USD","CAVA","ARI","AAL","LU1267930227.SGD","CHX","ALK","BK4534","BLUE","CELC","BJ","BK4588","AIN","ARE","SCHW","AGCO","AMH","BE"],"gpt_icon":1},{"id":"2483868343","title":"BUZZ-欧盟监管机构推荐阿尔茨海默氏症药物后，百健公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868343","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483868343?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:23","pubTimestamp":1731601431,"startTime":"0","endTime":"0","summary":"11月14日 - ** 制药公司百健BIIB.O股价上涨2%至169.14美元** 欧盟药品监管机构表示，建议批准  卫材4523.T和百健公司的药物Leqembi用于早期阿尔茨海默病患者。** 7月份，药品监管机构否决了Leqembi ，称其严重脑肿胀的风险不足以抵消其对减缓认知能力衰退的微小影响。** 截至目前，百健公司股价下跌了34.3%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML1MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4139","BK4585","LU0234570918.USD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4533","IE00B19Z9P08.USD","BK4532","BIIB","BK4588","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2483385848","title":"欧盟药品监管机构推荐卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385848","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483385848?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:07","pubTimestamp":1731600476,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透11月14日 - 欧盟药品监管机构周四表示，建议批准卫材  和百健  的Leqembi用于早期阿尔茨海默病患者的治疗，几个月前该机构首次拒绝了这种治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B19Z9P08.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4533","LU0234570918.USD","BK4139","BK4588","BIIB","LU0320765992.SGD","BK4532","BK4585"],"gpt_icon":0},{"id":"2483385793","title":"渤健公司盘中异动 股价大涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483385793?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:03","pubTimestamp":1731600220,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日00时03分，渤健公司股票出现异动，股价快速拉升5.24%。截至发稿，该股报174.47美元/股，成交量79.4063万股，换手率0.54%，振幅6.05%。机构评级方面，在所有37家参与评级的机构中，65%的券商给予买入建议，35%的券商给予持有建议，无券商给予卖出建议。渤健公司股票所在的制药行业中，整体跌幅为0.97%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111500034098e42b0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111500034098e42b0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B894F039.SGD","BK4139","BK4585","LU0234570918.USD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4533","IE00B19Z9P08.USD","BK4532","BIIB","BK4588","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2483050876","title":"美国研究综述-思科、Freshpet、Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050876","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483050876?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:06","pubTimestamp":1731585982,"startTime":"0","endTime":"0","summary":"美国研究综述-思科、Freshpet、Nvidia路透11月14日 - 华尔街证券分析师周四调整了对思科、Freshpet 和 Nvidia 等几家美国上市公司的评级和目标价。要闻 * 思科CSCO.O：杰富瑞将目标价从53美元上调至66美元 * Freshpet Inc FRPT.O：奥本海默将目标价从155美元上调至180美元  * ICU Medical Inc ICUI.O：Raymond James将目标价从190美元上调至205美元  * Kronos Bio Inc KRON.O：TD Cowen将目标价从买入下调至持有 * Nvidia Corp NVDA.O：奥本海默将目标价从 150 美元上调至 175 美元 以下是路透周四报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","AXTA","LU1244550577.SGD","CNNE","BK4209","ALSN","AVB","BK4550","BPMC","LU1244550494.USD","CSCO","LU0300736492.USD","LU1894683348.USD","ALLO","SG9999002232.USD","CHGG","IE00BZ1G4Q59.USD","CAKE","ALMS","CHX","APEI","CPAY","CPT","BRBR","DOX","FDMT","CPB","AZTA","IE00BFXG1179.USD","CRVS","CBSH","LU0868494708.USD","AROC","CAVA","COGT","BWXT","BTMD","AIT","LU2106854487.HKD","BIIB","SPRY","ACRV","ADAP","APD","SLRN","BKR","AESI","LU0234572021.USD","CTRA","EE"],"gpt_icon":0},{"id":"2481167540","title":"渤健公司2024财年第三财季实现净利润3.89亿美元，同比增加671.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481167540","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481167540?lang=zh_cn&edition=full","pubTime":"2024-11-08 00:00","pubTimestamp":1730995233,"startTime":"0","endTime":"0","summary":"11月8日，渤健公司公布财报，公告显示公司2024财年第三财季净利润为3.89亿美元，同比增加671.22%；其中营业收入为23.76亿美元，同比减少2.42%，每股基本收益为2.67美元。从资产负债表来看，渤健公司总负债119.54亿美元，其中短期债务17.48亿美元，资产负债比为2.37，流动比率为1.26。机构评级：截至2024年11月8日，当前有27家机构对渤健公司目标价做出预测，其中目标均价为254.56美元，其中最低目标价为180.00美元，最高目标价为342.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000045abaaa06a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000045abaaa06a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":0},{"id":"2480083599","title":"实时市场-脑力劳动正在进行，但神经药物开发人员仍需努力","url":"https://stock-news.laohu8.com/highlight/detail?id=2480083599","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480083599?lang=zh_cn&edition=full","pubTime":"2024-11-01 23:38","pubTimestamp":1730475534,"startTime":"0","endTime":"0","summary":"您可以通过以下网址与我们分享您的想法  脑力劳动正在进行，但神经药物开发商仍有很长的路要走Canaccord Genuity分析师周五表示，神经系统疾病方面的需求尚未得到满足，这激起了人们对正在开发的治疗抑郁症、阿尔茨海默病和痴呆症等神经系统疾病药物试验数据的期待，这些疾病影响着全球数百万患者。嘉能可补充说，尽管在理解阿尔茨海默氏症这种神经退行性疾病方面还存在挑战，但 Leqembi 和 Kisunla 的成功已经到来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BIIB","LU0061475181.USD","LU0320765646.SGD","SQQQ","PSQ","IE00BJJMRZ35.SGD","LU0097036916.USD","QLD","IE00BFTCPJ56.SGD","MNQmain","LU0456855351.SGD","BK4532","QID","LU0943347566.SGD","LU1066051225.USD","LU0096364046.USD","LU0122379950.USD","NMRA",".IXIC","LU0203201768.USD","LU0417517546.SGD","LU0708995401.HKD",".SPX","BK4504","DXD","LU1064131342.USD","DOG","IE0034235303.USD","DDM","LU0203347892.USD","CRVO","IE00B2B36J28.USD","LU0795875086.SGD","BMY",".DJI","NQmain","JNJ","IE00B42XCP33.USD","DJX","LU0234570918.USD","TQQQ","SDOW","LU0094547139.USD","BK4139","LU0354030511.USD","IE00B19Z9Z06.USD","UDOW"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0611},{"period":"3month","weight":-0.2653},{"period":"6month","weight":-0.3461},{"period":"1year","weight":-0.423},{"period":"ytd","weight":-0.434}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.032222},{"month":6,"riseRate":0.484848,"avgChangeRate":0.01808},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035186},{"month":8,"riseRate":0.575758,"avgChangeRate":0.030603},{"month":9,"riseRate":0.484848,"avgChangeRate":0.022099},{"month":10,"riseRate":0.529412,"avgChangeRate":0.057649},{"month":11,"riseRate":0.588235,"avgChangeRate":0.013418},{"month":12,"riseRate":0.470588,"avgChangeRate":0.034995}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}